|
|
| | 1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]- Basic information |
| | 1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]- Chemical Properties |
| Boiling point | 752.9±60.0 °C(Predicted) | | density | 1.47±0.1 g/cm3(Predicted) | | pka | 7.82±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | 1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]- Usage And Synthesis |
| Uses | Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM)[1]. | | References | [1] Buckeridge C, et al. Once-daily oral small molecule GLP-1R agonist PF-07081532 reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity. Hybrid 58th EASD Annual Meeting; Sept 19–23, 2022 (abstr 114). [2] Sloop KW, et al., The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron. Sci Transl Med. 2024 Dec 18;16(778):eadp5765. DOI:10.1126/scitranslmed.adp5765 |
| | 1H-Benzimidazole-6-carboxylic acid, 2-[[4-[(2S)-2-(5-chloro-2-pyridinyl)-2-methyl-1,3-benzodioxol-4-yl]-1-piperidinyl]methyl]-1-[(2S)-2-oxetanylmethyl]- Preparation Products And Raw materials |
|